TickerTalks
Browse all tickers →
TickerTalks›$MTD
MTMTD

Mettler-Toledo International Inc.

$MTD·$26B·Medical - Diagnostics & Research·Healthcare
$1320.23+0.4%YTD-6.0%1Y+10.1%
Mentions · last 7 days
2026-07-08: 1 posts2026-07-09: 0 posts2026-07-10: 1 posts2026-07-11: 0 posts2026-07-12: 1 posts2026-07-13: 4 posts2026-07-14: 3 posts10+33%
Price updated 14m ago·X counts updated 19h ago
MTMTD
$MTDMettler-Toledo International Inc.
$1,320.23+0.41%10 posts+33%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $MTD, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Proven numbersWinding up for a moveAI verdict · as of 2026-07-14

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Mettler-Toledo is a defensive precision-instruments compounder near its 200-day — $1,299.53 is -7% YTD but +9% over 12 months, and coiling into the July 30 print.

Mettler-Toledo makes precision instruments and services for laboratory, industrial and food-retail applications — a Berkshire-caliber quality compounder with world-class economics that has been resting through a rate-linked drawdown.

  • Fundamentals are excellent — Q1 revenue $947M up 7.2% YoY, operating margin 26%, ROIC 36%, PE 27x — one of the cleanest instrument-industry profiles you can find, with consistent mid-single-digit revenue growth and mid-20% margins.
  • Balance sheet math is unusual — buybacks have driven equity negative (D/E -53), so read the return metrics accordingly; the operating cash flow is what matters and it is robust.
  • Setup is technically neutral — 10% above the 50-day, essentially at the 200-day, mid 52-week range — GF Value estimates around $1,431 suggest modest upside; the July 30 print is the release event.

No aggregated X sentiment was available. Coverage frames the equity as fairly-to-undervalued, and a GF Score in the 90s supports the quality-compounder read.

What to watch: July 30 Q2 earnings — segment revenue growth, operating margin, and any updated FY guide.

On the calendar: 2026-07-30 Q2 earnings

sentiment thin

Read the AI verdict + X sentiment for $MTD

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Makes precision laboratory balances, analytical instruments, and process weighing systems for pharma and food industries.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Diagnostics & Research sits in its cycle right now — and what that implies for $MTD.

Medical - Diagnostics & Research · Healthcare

No material change from last week — pharma R&D spending is recovering and CDMO demand is growing as drug pipelines advance toward clinical trials.

What this means for $MTD

Neutral — Makes precision laboratory balances, analytical instruments, and process weighing systems for pharma and food industries; the pharma R&D recovery and CDMO outsourcing demand expansion does not materially affect this business's near-term earnings.

Industry benchmark

12-name peer basket
+29.4%YTD
+54.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
26.8How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
36.1%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
28.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
3.4%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
5.7Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-6.1%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
57.8%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
-53.2Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 7, 2026$8.91$8.71+2.3%
Q4 2025Feb 5, 2026$13.36$12.80+4.4%
Q3 2025Nov 6, 2025$11.15$10.66+4.6%
Q2 2025Jul 31, 2025$10.09$9.60+5.1%
Next earningsThu, Jul 30·consensus EPS $10.78

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$947.1M+7.2%58.7%26.0%$8.35$122.4M
Q4 FY25$1.1B+8.1%58.0%30.4%$14.02$184.1M
Q3 FY25$1.0B+7.9%57.2%28.2%$10.60$274.9M
Q2 FY25$983.2M+3.9%57.2%27.0%$9.77$212.5M

Forward consensus

5-year forecast · up to 9 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$4.2B$4.2B – $4.3B$46.68$46.49 – $46.859
FY27$4.4B$4.4B – $4.4B$51.14$50.47 – $51.819
FY28$4.7B$4.7B – $4.7B$56.90$56.84 – $56.958
FY29$4.9B$4.9B – $4.9B$62.67$62.24 – $63.127
FY30$5.2B$5.1B – $5.2B$68.76$68.28 – $69.257

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.6×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.58%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+11.1%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+0.0%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 20.1M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.7% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.255-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellFeb 10Shawn VadalaCFO800 sh$1.1M
+ 8 other (7 awards · 1 exempt) in window

See when $MTD insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KOfficer or director changeMay 138-K — Item 5.02: Officer or director change
AI summary

MTD disclosed a personnel change (8-K Item 5.02, dated 2026-05-13). A new executive or director appointment is reported. Personnel changes are generally administrative; materiality depends on seniority and circumstances.

8-KShareholder voteMay 118-K — Item 5.07: Shareholder vote
AI summary

MTD held its annual meeting of stockholders around 2026-05-11 (8-K Item 5.07). The meeting was adjourned, likely due to insufficient quorum. Routine governance event — monitor for unusually high withhold votes as an activist signal.

3New insider — initial holdingsFeb 63
8-KOfficer or director changeJan 208-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
+ 12 other (3 13Gs · 2 earnings 8-Ks · 2 proxys · 1 11-K) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Mettler-Toledo International Inc. to Host Second Quarter 2026 Earnings Conference Callbusinesswire.com·9d agoMettler-Toledo (MTD) Soars 3.3%: Is Further Upside Left in the Stock?zacks.com·19d agoA Look at Mettler-Toledo International Inc (MTD) After 4.0% Gain -- GF Value $1431.38 vs Price $1203.18gurufocus.com·21d agoIs It Too Late to Buy Mettler-Toledo International Inc (MTD) After 4.2% Rally? GF Value Says Undervaluedgurufocus.com·58d agoMettler-Toledo International Inc. (MTD) Presents at Bank of America Global Healthcare Conference 2026 Transcriptseekingalpha.com·63d ago

In themes

Explore the broader themes this ticker is being talked about under.

GLP-1 & Weight Loss

More in Medical - Diagnostics & Research

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$TMO$IQV$DHR$A$NTRA$ILMN$TWST$GH
Voices on X · last 7 days

No standout posts about $MTD on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport